STOCK TITAN

Xtant Medical Reports Third Quarter 2024 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Xtant Medical reported Q3 2024 financial results with revenue of $27.9 million, up 12% year-over-year, and year-to-date revenue of $85.8 million, up 36%. The company posted a net loss of $5.0 million compared to net income of $9.2 million in Q3 2023. Gross margin decreased to 58.4% from 61.3%. Notable developments include launching OsteoVive+ and Cortera Posterior Fixation System, signing a license agreement worth minimum $5.25 million, and completing a $5.0 million private placement. The company reaffirmed its full-year 2024 revenue guidance of $116-120 million, representing 27-31% growth.

Xtant Medical ha riportato i risultati finanziari del Q3 2024 con un fatturato di 27,9 milioni di dollari, in aumento del 12% rispetto all'anno precedente, e un fatturato da inizio anno di 85,8 milioni di dollari, in crescita del 36%. L'azienda ha registrato una perdita netta di 5,0 milioni di dollari rispetto a un utile netto di 9,2 milioni di dollari nel Q3 2023. Il margine lordo è diminuito al 58,4% dal 61,3%. Sviluppi significativi includono il lancio di OsteoVive+ e del Sistema di Fissazione Posteriore Cortera, la firma di un accordo di licenza del valore minimo di 5,25 milioni di dollari e il completamento di un collocamento privato di 5,0 milioni di dollari. L'azienda ha confermato la sua guida per il fatturato dell'intero anno 2024, prevedendo un fatturato di 116-120 milioni di dollari, che rappresenta una crescita del 27-31%.

Xtant Medical informó los resultados financieros del Q3 2024 con ingresos de 27.9 millones de dólares, un aumento del 12% en comparación con el año anterior, y unos ingresos acumulados hasta la fecha de 85.8 millones de dólares, un incremento del 36%. La compañía reportó una pérdida neta de 5.0 millones de dólares en comparación con un ingreso neto de 9.2 millones de dólares en el Q3 2023. El margen bruto disminuyó al 58.4% desde el 61.3%. Los desarrollos notables incluyen el lanzamiento de OsteoVive+ y el Sistema de Fijación Posterior Cortera, la firma de un acuerdo de licencia por un valor mínimo de 5.25 millones de dólares y la finalización de una colocación privada de 5.0 millones de dólares. La empresa reafirmó su guía de ingresos para todo el año 2024 de 116-120 millones de dólares, lo que representa un crecimiento del 27-31%.

Xtant Medical은 2024년 3분기 재무 결과를 보고하며, 수익은 2790만 달러로 전년 대비 12% 증가하였고, 올해 누적 수익은 8580만 달러로 36% 증가하였습니다. 회사는 2023년 3분기에 920만 달러의 순이익을 기록한 것에 비해 500만 달러의 순손실을 기록했습니다. 총 이익률은 61.3%에서 58.4%로 감소했습니다. 주목할만한 발전 사항으로는 OsteoVive+와 Cortera Posterior Fixation System의 출시, 최소 525만 달러의 가치가 있는 라이선스 계약 체결, 500만 달러의 사모 배치 완료가 있습니다. 회사는 2024년 전체 연도 매출 가이던스를 1억 1600만~1억 2000만 달러로 확인하며, 이는 27-31%의 성장을 나타냅니다.

Xtant Medical a annoncé les résultats financiers du T3 2024 avec un chiffre d'affaires de 27,9 millions de dollars, en hausse de 12% par rapport à l'année précédente, et un chiffre d'affaires depuis le début de l'année de 85,8 millions de dollars, en augmentation de 36%. L'entreprise a affiché une perte nette de 5,0 millions de dollars par rapport à un bénéfice net de 9,2 millions de dollars au T3 2023. La marge brute a diminué à 58,4% contre 61,3%. Parmi les développements notables, on peut citer le lancement d'OsteoVive+ et du Système de Fixation Postérieure Cortera, la signature d'un accord de licence d'une valeur minimale de 5,25 millions de dollars, et l'achèvement d'un placement privé de 5,0 millions de dollars. L'entreprise a réaffirmé ses prévisions de chiffre d'affaires pour l'année 2024, s'élevant à 116-120 millions de dollars, représentant une croissance de 27-31%.

Xtant Medical hat die finanziellen Ergebnisse für das 3. Quartal 2024 veröffentlicht, mit einem Umsatz von 27,9 Millionen Dollar, was einem Anstieg von 12% im Jahresvergleich entspricht, und einem bisher in diesem Jahr erzielten Umsatz von 85,8 Millionen Dollar, was einem Anstieg von 36% entspricht. Das Unternehmen meldete einen Nettoverlust von 5,0 Millionen Dollar im Vergleich zu einem Nettoertrag von 9,2 Millionen Dollar im 3. Quartal 2023. Die Bruttomarge sank von 61,3% auf 58,4%. Zu den bemerkenswerten Entwicklungen gehören die Einführung von OsteoVive+ und dem Cortera Posterior Fixation System, der Abschluss eines Lizenzvertrags im Wert von mindestens 5,25 Millionen Dollar und die Durchführung einer privaten Platzierung im Wert von 5,0 Millionen Dollar. Das Unternehmen bekräftigte seine Umsatzprognose für das Gesamtjahr 2024 von 116-120 Millionen Dollar, was einem Wachstum von 27-31% entspricht.

Positive
  • Revenue growth of 12% YoY to $27.9 million in Q3 2024
  • Year-to-date revenue up 36% to $85.8 million
  • Signed license agreement worth minimum $5.25 million
  • Reaffirmed strong full-year revenue guidance of $116-120 million
Negative
  • Net loss of $5.0 million in Q3 2024 vs net income of $9.2 million in Q3 2023
  • Gross margin declined to 58.4% from 61.3% YoY
  • Adjusted EBITDA turned negative to -$196,000 from +$440,000 YoY
  • Operating expenses increased 7.3% to $20.1 million

Insights

The Q3 results present a mixed financial picture. While revenue grew 12% to $27.9 million, the company posted a net loss of $5.0 million, contrasting with last year's $9.2 million profit which included a one-time gain. The gross margin decline to 58.4% from 61.3% and negative Adjusted EBITDA of $196,000 signal operational challenges.

The reaffirmed full-year revenue guidance of $116-120 million suggests management's confidence in Q4 performance. The recent $5.0 million private placement and new licensing agreement with minimum $5.25 million in fees provide needed capital support. However, increased operating expenses and reduced production throughput need addressing for sustainable profitability.

The launch of OsteoVive+ and Cortera Posterior Fixation System represents strategic product portfolio expansion. The in-house production of OsteoVive+ is particularly significant as it offers both supply chain control and margin improvement potential. The biologics market focus aligns with industry growth trends, though the reported reduction in surgical procedures using their products warrants monitoring.

The integration of Surgalign Holdings' acquisition appears to be progressing, contributing to revenue growth. However, the transition period is impacting operational metrics, suggesting optimization opportunities in manufacturing and distribution efficiency.

Third Quarter Revenue Growth of 12%

Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million

Representing Growth of 27% to 31%

BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024.

Third Quarter 2024 Financial Highlights

  • Revenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year period

  • Gross margin of 58.4% compared to 61.3% for the prior year quarter

  • Net loss of $5.0 million compared to net income of $9.2 million in the prior year quarter which included a $11.0 million bargain purchase gain related to the acquisition of Surgalign Holdings

  • Adjusted EBITDA of $(196,000) compared to $440,000 in the prior year quarter

Recent Business Highlights

  • Launched OsteoVive+, a moldable, viable bone matrix for use in a variety of grafting procedures

  • Launched Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries

  • Signed a license agreement for Q-Codes and corresponding SimpliMax Dual Layer Amniotic Membrane, which provides for a minimum of $5.25 million in licensing and royalty fees

  • Completed $5.0 million private placement on August 9, 2024

Sean Browne, President and CEO of Xtant Medical, stated, "During the third quarter, we expanded our market opportunities with the launch of two new products, OsteoVive+ (stem cells) and Cortera Posterior Fixation System. Importantly, OsetoVive+ is produced internally to our high standards, giving us greater control over the supply chain and enabling a higher margin contribution on incremental sales, which we expect to accelerate in the fourth quarter."

Browne continued, "2024 is shaping up largely as we planned with revenue growth of 36% year-to-date. We are therefore reaffirming our full year revenue guidance of $116 million to $120 million. The growth we expect in the fourth quarter will be driven by the strength of our products, continued strong operational execution and importantly, it will be entirely organic. The market opportunities in biologics are expansive, and we are striving to build a resilient and scalable business, which we believe will drive long-term growth and increase profitability for our stockholders."

Third Quarter 2024 Financial Results

Total revenue for the three months ended September 30, 2024 was $27.9 million, an increase of 12%, compared to $25.0 million in the prior year quarter. The increase is primarily due to the contribution of additional sales resulting from the acquisition of the Surgalign Holdings' hardware and biologics business, which was partially offset by reduced surgical procedures using our products.

Gross margin for the third quarter of 2024 was 58.4%, compared to 61.3% for the prior year quarter. The decrease is primarily due to reduced production throughput, partially offset by additional scale.

Operating expenses for the third quarter of 2024 totaled $20.1 million, an increase of 7.3% compared to $18.7 million for the third quarter of 2023. The increase was primarily due to additional commission expense resulting from revenue growth, additional compensation expense related to additional headcount and additional stock-based compensation.

Net loss for the third quarter of 2024 was $5.0 million, or $(0.04) per share, compared to net income of $9.2 million, or $0.07 per share in the prior year quarter. Net income for the third quarter of 2023 includes a bargain purchase gain of $11.0 million related to the acquisition of Surgalign Holdings' hardware and biologics business in August 2023.

Non-GAAP Adjusted EBITDA for the third quarter of 2024 was a loss of $196,000, compared to non-GAAP Adjusted EBITDA of $440,000 for the prior-year period. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, separation related expenses, legal settlements, non-cash compensation, acquisition-related expenses, acquisition-related fair value adjustments, gain on bargain purchase and foreign currency exchange gains/losses. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.

As of September 30, 2024, the Company had $6.6 million of cash and cash equivalents compared to $5.7 million as of December 31, 2023.

2024 Financial Guidance

Xtant Medical reaffirmed its full year 2024 revenue guidance of $116 million to $120 million. Revenue guidance for 2024 represents annual growth of 27% to 31%.

Conference Call

Xtant Medical will host a webcast and conference call to discuss third quarter 2024 financial results at 4:30 pm ET on Tuesday, November 12, 2024.

To access the webcast, visit https://www.webcaster4.com/Webcast/Page/3039/51623.

To access the conference call, dial 888-999-3182 within the U.S. or 848-280-6330 outside the U.S. Passcode: Xtant Medical Holdings.

A replay of the call will be available on the Investor section of the Company's website at www.xtantmedical.com.

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ‘‘expects,'' ‘‘anticipates,'' ‘‘plans,'' ‘‘believes,'' ‘‘estimates,'' "continue," "future," ‘‘will,'' "potential," "going forward," "guidance," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's financial guidance for 2024, expectations for the acceleration of incremental sales in the fourth quarter, the Company's ability to build a resilient and scalable business, the Company's anticipated long-term growth and increased profitability for stockholders. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results and financial performance; its ability to increase or maintain revenue; the Company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with its acquisitions and the integration of those businesses; anticipated shortages of stem cells which will adversely affect future revenues; the ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products and the success of those products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company's dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on the Company's business, operating results and financial condition, especially when they affect key markets; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company's financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to license certain of the Company's intellectual property on commercially reasonable terms and to maintain any such licenses; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company's clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to maintain sufficient liquidity to fund its operations and obtain financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on April 1, 2024 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 anticipated to be filed with the SEC. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact:

Brett Maas
Managing Partner, Hayden IR
brett@haydenir.com
(646) 536-7331

XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except number of shares and par value)

September 30, 2024

December 31, 2023

ASSETS

Current Assets:

Cash and cash equivalents

$

6,596

$

5,715

Restricted cash

490

208

Trade accounts receivable, net of allowance for
credit losses and doubtful accounts of $1,038 and $920,
respectively

20,545

20,731

Inventories

41,886

36,885

Prepaid and other current assets

1,893

1,330

Total current assets

71,410

64,869

Property and equipment, net

10,284

8,692

Right-of -use asset, net

995

1,523

Goodwill

7,302

7,302

Intangible assets, net

8,788

10,085

Other assets

103

141

Total Assets

$

98,882

$

92,612

LIABILITIES & STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable

$

8,298

$

7,054

Accrued liabilities

8,871

10,419

Current portion of lease liability

795

830

Current portion of finance lease obligations

68

65

Line of credit

12,887

4,622

Current portion of long-term debt

2,750

-

Total current liabilities

33,669

22,990

Long-term Liabilities:

Lease liability, less current portion

247

759

Finance lease obligations, less current portion

65

116

Long-term debt, plus premium and less issuance costs

19,138

17,167

Other liabilities

38

231

Total Liabilities

53,157

41,263

Commitments and Contingencies

-

-

Stockholders' Equity

Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding

-

-

Common stock, $0.000001 par value; 300,000,000 shares authorized; 138,680,874 shares issued and outstanding as of September 30, 2024 and 130,180,031 shares issued and outstanding as of December 31, 2023

-

-

Additional paid-in capital

301,966

294,330

Accumulated other comprehensive (loss) income

54

29

Accumulated deficit

(256,295

)

(243,010

)

Total Stockholders' Equity

45,725

51,349

Total Liabilities & Stockholders' Equity

$

98,882

$

92,612

XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except number of shares and per share amounts)

Three Months Ended
September 30,

Nine Months Ended
September 30,

2024

2023

2024

2023

Revenue

$

27,937

$

25,019

$

85,754

$

63,195

Cost of sales

11,630

9,685

33,562

24,865

Gross Profit

16,307

15,334

52,192

38,330

Gross Profit %

58.4

%

61.3

%

60.9

%

60.7

%

Operating Expenses

General and administrative

7,493

7,144

22,991

16,983

Sales and marketing

11,890

11,085

37,530

26,855

Research and development

701

490

1,863

844

Total Operating Expenses

20,084

18,719

62,384

44,682

Loss from Operations

(3,777

)

(3,385

)

(10,192

)

(6,352

)

Other (Expense) Income

Interest expense

(1,199

)

(760

)

(3,026

)

(2,120

)

Interest income

-

48

-

133

Foreign currency exchange gain

27

-

106

-

Other expense

(13

)

-

(6

)

-

Bargain purchase gain

-

11,028

-

11,028

Total Other (Expense) Income

(1,185

)

10,316

(2,926

)

9,041

Net (Loss) Income from Operations Before Provision for Income Taxes

(4,962

)

6,931

(13,118

)

2,689

Provision for Income Taxes

Current and Deferred

(62

)

2,300

(166

)

2,274

Net (Loss) Income

$

(5,024

)

$

9,231

$

(13,284

)

$

4,963

Net (Loss) Income Per Share:

Basic

$

(0.04

)

$

0.07

$

(0.10

)

$

0.04

Dilutive

$

(0.04

)

$

0.07

$

(0.10

)

$

0.04

Shares used in the computation:

Basic

135,100,233

128,140,238

131,881,302

115,380,792

Dilutive

135,100,233

135,663,274

131,881,302

123,832,401

XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)

Nine Months Ended
September 30,

2024

2023

Operating activities:

Net (loss) income

$

(13,284

)

$

4,963

Adjustments to reconcile net (loss) income to net cash used in operating activities:

Depreciation and amortization

3,076

2,157

Gain on disposal of fixed assets

(182

)

(104

)

Non-cash interest

369

266

Non-cash rent

(18

)

5

Stock-based compensation

3,277

1,801

Provision for expected credit losses

330

316

Provision for excess and obsolete inventory

695

398

Release of valuation allowance

-

(2,394

)

Gain on bargain purchase

-

(11,028

)

Other

17

-

Changes in operating assets and liabilities, net of the effects of the acquisition:

Accounts receivable

(128

)

(7,047

)

Inventories

(5,657

)

(1,669

)

Prepaid and other assets

(503

)

69

Accounts payable

1,290

1,298

Accrued liabilities

(1,843

)

2,369

Net cash used in by operating activities

(12,561

)

(8,600

)

Investing activities:

Purchases of property and equipment

(3,441

)

(1,093

)

Proceeds from sale of fixed assets

278

70

Acquisition of Surgalign SPV, Inc.

-

(17,000

)

Acquisition of Surgalign Holding, Inc.'s hardware and biologics business, net of cash acquired

-

(4,448

)

Net cash used in investing activities

(3,163

)

(22,471

)

Financing activities:

Payments on financing leases

(49

)

(46

)

Borrowings on line of credit

86,315

55,345

Repayments of line of credit

(78,050

)

(54,724

)

Proceeds from private placement, net of cash issuance costs

4,456

14,011

Proceeds from issuance of long-term debt, net of issuance costs

5,000

4,899

Payments on long term debt

(648

)

-

Proceeds from exercise of stock based compensation

13

-

Payment of taxes from withholding of common stock on vesting of restricted stock units

(110

)

(119

)

Net cash provided by financing activities

16,927

19,366

Effect of exchange rate changes on cash and cash equivalents and restricted cash

(40

)

(53

)

Net change in cash and cash equivalents and restricted cash

1,163

(11,758

)

Cash and cash equivalents and restricted cash at beginning of period

5,923

20,507

Cash and cash equivalents and restricted cash at end of period

$

7,086

$

8,749

Reconciliation of cash and restricted cash reported in the condensed consolidated balance sheets

Cash and cash equivalents

$

6,596

$

8,664

Restricted cash

490

85

Total cash and restricted cash reported in the condensed consolidated balance sheets

$

7,086

$

8,749

XTANT MEDICAL HOLDINGS, INC.
Calculation of Non-GAAP Consolidated EBITDA and Adjusted EBITDA
(Unaudited, in thousands)

Three Months Ended September 30,

Nine Months Ended September 30,

2024

2023

2024

2023

Net (Loss) Income

$

(5,024

)

$

9,231

$

(13,284

)

$

4,963


Depreciation and amortization

1,073

883

3,076

2,157

Interest expense

1,199

712

3,026

1,987

Tax expense (benefit)

62

(2,300

)

166

(2,274

)

Non-GAAP EBITDA

(2,690

)

8,526

(7,016

)

6,833


Non-GAAP EBITDA/Total revenue

-9.6

%

34.1

%

-8.2

%

10.8

%


NON-GAAP ADJUSTED EBITDA CALCULATION

Separation related expenses

464

-

490

(15

)

Legal settlements

-

140

-

140

Non-cash compensation

1,139

745

3,277

1,801

Acquisition-related expenses

-

1,023

338

1,326

Acquisition-related fair value adjustments

918

1,026

3,448

1,188

Gain on bargain purchase

-

(11,028

)

-

(11,028

)

Unrealized foreign currency translation (gain) loss

(27

)

8

(106

)

8

Non-GAAP Adjusted EBITDA

$

(196

)

$

440

$

431

$

253


SOURCE: Xtant Medical Holdings, Inc.



View the original press release on accesswire.com

FAQ

What was Xtant Medical's (XTNT) revenue in Q3 2024?

Xtant Medical reported revenue of $27.9 million in Q3 2024, representing a 12% increase compared to the same period last year.

What is Xtant Medical's (XTNT) full-year 2024 revenue guidance?

Xtant Medical reaffirmed its full-year 2024 revenue guidance of $116-120 million, representing growth of 27-31%.

What new products did Xtant Medical (XTNT) launch in Q3 2024?

Xtant Medical launched two new products: OsteoVive+, a moldable viable bone matrix, and the Cortera Posterior Fixation System for thoracolumbar fixation surgeries.

Xtant Medical Holdings, Inc.

NYSE:XTNT

XTNT Rankings

XTNT Latest News

XTNT Stock Data

56.99M
55.14M
7.83%
65.12%
0.14%
Medical Devices
Biological Products, (no Disgnostic Substances)
Link
United States of America
BELGRADE